Epizyme (EPZM) Trading Up 2.4%

Share on StockTwits

Shares of Epizyme Inc (NASDAQ:EPZM) were up 2.4% on Wednesday . The company traded as high as $12.60 and last traded at $12.88. Approximately 383,820 shares changed hands during trading, a decline of 55% from the average daily volume of 857,015 shares. The stock had previously closed at $12.58.

A number of analysts have weighed in on EPZM shares. ValuEngine lowered shares of Epizyme from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. BidaskClub upgraded shares of Epizyme from a “hold” rating to a “buy” rating in a research report on Tuesday, February 5th. Cowen restated a “buy” rating and set a $18.00 target price on shares of Epizyme in a research report on Tuesday, February 26th. Oppenheimer cut their target price on shares of Epizyme from $27.00 to $18.00 and set an “outperform” rating for the company in a research report on Wednesday, February 27th. Finally, Roth Capital restated a “buy” rating on shares of Epizyme in a research report on Wednesday, February 27th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $18.90.

The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.55 and a current ratio of 12.55. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -7.51 and a beta of 3.08.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.07. The firm had revenue of $7.89 million for the quarter, compared to analysts’ expectations of $1.13 million. Analysts predict that Epizyme Inc will post -1.98 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the business. Redmile Group LLC lifted its holdings in Epizyme by 15.9% during the first quarter. Redmile Group LLC now owns 7,694,020 shares of the biopharmaceutical company’s stock valued at $95,329,000 after purchasing an additional 1,056,742 shares in the last quarter. Metropolitan Life Insurance Co NY lifted its holdings in Epizyme by 18.3% during the first quarter. Metropolitan Life Insurance Co NY now owns 19,570 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 3,029 shares in the last quarter. Slow Capital Inc. purchased a new position in Epizyme during the first quarter valued at approximately $317,000. FMR LLC lifted its holdings in Epizyme by 0.3% during the first quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock valued at $43,169,000 after purchasing an additional 11,759 shares in the last quarter. Finally, BlueMountain Capital Management LLC lifted its holdings in Epizyme by 4,019.4% during the first quarter. BlueMountain Capital Management LLC now owns 55,900 shares of the biopharmaceutical company’s stock valued at $693,000 after purchasing an additional 54,543 shares in the last quarter. 74.44% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Epizyme (EPZM) Trading Up 2.4%” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/4349527/epizyme-epzm-trading-up-2-4.html.

Epizyme Company Profile (NASDAQ:EPZM)

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Recommended Story: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

China Shenhua Energy –  to Issue $0.42 Annual Dividend
China Shenhua Energy – to Issue $0.42 Annual Dividend
Wall Financial Co.  Plans Dividend Increase – $2.00 Per Share
Wall Financial Co. Plans Dividend Increase – $2.00 Per Share
Guaranty Bancshares, Inc.  Declares Quarterly Dividend of $0.17
Guaranty Bancshares, Inc. Declares Quarterly Dividend of $0.17
Bancolombia SA  To Go Ex-Dividend on June 26th
Bancolombia SA To Go Ex-Dividend on June 26th
Vail Resorts, Inc.  Announces $1.76 Quarterly Dividend
Vail Resorts, Inc. Announces $1.76 Quarterly Dividend
Dynex Capital Inc Announces Monthly Dividend of $0.18
Dynex Capital Inc Announces Monthly Dividend of $0.18


© 2006-2019 Ticker Report